Table 4.
Nanoparticles made of chitosan derivatives for the treatment of HCC and liver-targeting: the therapeutic/theranostic effect and cell cultures used in the study are reported for each reference.
| Carrier | Payload | Effect | Cell Culture | Reference |
|---|---|---|---|---|
| Folate-conjugated chitosan | IP-10 gene | anticancer gene therapy | - | [88] |
| Folate-conjugated chitosan | IP-10 gene | anticancer gene therapy | H22 | [89] |
| Folated poly(ethylene glycol)-chitosan-graft-polyethylenimine | plasmid DNA | anticancer gene therapy | - | [90] |
| Biotinylated chitosan | plasmid DNA | anticancer gene therapy | SMMC-7721 | [91,92,93] |
| Biotin or biotin/avidin conjugated chitosan | trans-resveratrol | anticancer antioxidant |
- | [94] |
| N,N,N-trimethyl chitosan | monoclonal antibodies | anticancer | HepG2 | [95,96] |
| N,N,N-trimethyl chitosan | lactosyl-norcantharidin | anticancer | - | [97,98,99] |
| 2-chloroethylamine HCl/N,N-dimethyl-2-chloroethylamine HCl combined chitosan | maidkin-siRNA | anticancer gene therapy | - | [100] |
| N-succinyl chitosan | siRNA and doxorubicin | anticancer gene therapy | - | [101] |
| Lactose marital carboxymethyl chitosan | adriamycin | anticancer | HU7; H22 | [102,103] |
| Glycol Chitosan-5β-Cholanic Acid | - | tumor targeting | HT29 | [104] |